Genes Such as IRS2 Differ from Ewing Sarcoma and Normal Tissue-specific Expression for Osteosarcoma

Abstract

Objective: To screen and validate the expression of other key genes specific to osteosarcoma that distinguish normal tissue from Ewing sarcoma using a bioinformatics approach. Methods: GSE73166 for osteosarcoma associated with Ewing sarcoma and GSE42352 for osteosarcoma associated with normal tissue were obtained from the GEO database, and these two datasets were screened for differential genes (DEGs) and subjected to corresponding GO enrichment and KEGG enrichment with GSEA validation, and then correlation analysis, PCA and immuno-infiltration analysis were performed on the two datasets, and the These two datasets were intersected to derive 28 differential genes, and the corresponding heat map analysis and protein interaction network analysis were performed for these 28 genes, and then the expression statistics of these 28 genes in GSE21257 for different graded genes and survival analysis in R2 for osteosarcoma in TARGET. Results: TNFRSF11B, COL12A1, PLOD2, PTGES, MEF2C, IRS2 and MMP13 were found to have an effect on the staging of osteosarcoma, while CCND1 (P=0.021), IRS2 (P=0.015), OLFML2B (P=0.035), CPE (P=0.037), MAMDC2 (P=0.044) and MMP13 (P=0.013) had an impact on the survival prognosis of osteosarcoma. Conclusions: IRS2 and 11 other genes differ from Ewing sarcoma and normal tissues, producing a specific expression on the staging or survival prognosis of osteosarcoma.